logo
New COVID Variant Nimbus May Cause Painful ‘Razor Blade Throat' Symptom

New COVID Variant Nimbus May Cause Painful ‘Razor Blade Throat' Symptom

Health Line19-06-2025
The Nimbus variant of COVID-19 is on the rise, as many have reported a painful symptom they're calling 'razor blade throat.'
If you have a severe sore throat, it's important to get tested to rule out strep throat to avoid severe complications.
COVID-19 precautions like masking and vaccination remain important.
A newly identified COVID-19 variant called 'Nimbus' is rapidly spreading in the United States and making headlines with a common symptom that's turning heads in exam rooms.
People contracting a COVID-19 infection are reporting an unusually intense sore throat, described as feeling like swallowing razor blades.
Some think this symptom, dubbed 'razor blade throat,' may set this variant apart from earlier ones.
However, experts aren't so sure. Sore throat has long been recognized as a COVID-19 symptom.
Early data suggest Nimbus may not cause more severe illness overall, but reports of severe sore throats are raising questions about how this variant might differ from its predecessors.
Here's what experts told Healthline about the Nimbus variant — and what you should know.
Nimbus is more transmissible, but not as severe
According to the World Health Organization (WHO), Nimbus, also known as NB.1.8.1, is a subvariant of the Omicron variant of the SARS-CoV-2 virus that causes COVID-19.
Yale School of Medicine Assistant Professor Scott Roberts, MD, explained that Nimbus currently accounts for about one-third of COVID-19 cases in the United States.
'It is more transmissible than the current circulating variants because of several mutations in the spike protein that make it distinct from the others,' he told Healthline.
'But, it is still an omicron subvariant related to some variants that were circulating previously, so I suspect there will be an increase in cases, but not a wave to the degree we have had previously.'
Kartik Cherabuddi, MD, FIDSA, Chief Hospital Epidemiology Officer at Tampa General Hospital, noted that while Nimbus is currently surging around the world, the public health risk is still low compared to other Omicron lineages.
'Early and limited laboratory data do not show a significant capability to evade the immune system or increased resistance to antiviral treatment,' he told Healthline.
Cherabuddi added that no reported studies are currently available on the impact of Nimbus on clinical outcomes.
However, '[r]outine surveillance, so far, does not reveal an increase in hospitalization or death,' he said.
'Razor blade throat' may not be a new COVID symptom
Roberts said the symptoms of the Nimbus variant are the same as those of prior COVID-19 variants, including fever, cough, and sore throat.
'The 'razor blade throat' is anecdotal and there is no evidence to suggest that this variant leads to more severe sore throat than other variants,' he added.
Roberts advised, however, if you do have a sore throat, it would be a good idea to test for COVID-19 to make sure it is not the cause.
If your sore throat is severe, he also recommends checking in with your doctor to rule out strep throat.
Other common symptoms of COVID-19 include loss of taste or smell and fatigue.
Less frequently, individuals may experience:
sore throat
headaches
body aches
diarrhea
skin rash
discoloration of fingers or toes
red, irritated eyes
Symptoms of strep throat may include:
sudden fever
sore throat with white patches
headache
chills
loss of appetite
swollen lymph nodes
problems with swallowing
Experts say it's important to distinguish strep throat from COVID-19.
Unlike COVID-19, which is caused by a virus, strep throat is a bacterial infection caused by group A Streptococcus.
Strep throat often requires antibiotic treatment to prevent potentially serious complications.
These may include peritonsillar abscesses (pus-filled infections behind the tonsils), rheumatic fever (which can damage the heart, joints, and skin), post-streptococcal glomerulonephritis (a type of kidney inflammation), and, in rare cases, streptococcal toxic shock syndrome or meningitis.
How to protect yourself from the Nimbus variant
The first thing to know about protecting yourself from the Nimbus variant is that nothing has really changed in this department.
'The same tools that worked before will still work: handwashing, avoiding people who are sick, good ventilation, getting vaccinated, and masking in high risk settings,' said Roberts.
The CDC recommends the vaccine for most adults ages 18 and older to maintain protection against severe illness, hospitalization, and death.
Older adults, high risk individuals, and those who've never been vaccinated are especially encouraged to get it. Parents should consult a healthcare professional for kids under 18.
The CDC additionally notes that immunity from previous vaccines wanes over time, making updated vaccination important.
COVID-19 vaccine recommendations may also change soon, making it more difficult for healthy adults, children, and pregnant people to get one.
Cherabuddi added there are certain symptoms that would indicate you need to consult with a physician, such as:
severe throat pain
throat pain that lasts longer than a week
weight loss
food sticking in your throat
new or worsened shortness of breath
'If any of these red flags occur, have it checked out,' he said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Boston Scientific lifts annual profit view on steady heart devices demand
Boston Scientific lifts annual profit view on steady heart devices demand

Yahoo

time24 minutes ago

  • Yahoo

Boston Scientific lifts annual profit view on steady heart devices demand

(Reuters) -Boston Scientific raised its annual profit forecast on Wednesday, after strong demand for its heart devices helped the U.S. medical device maker beat second-quarter profit estimates. Shares of the Massachusetts-based company rose 2.3% in premarket trading following the results. A rise in surgical procedures has benefited medical device manufacturers such as Boston Scientific, as it boosted sales and helped offset broader concerns about healthcare spending pressures. Analysts said hospital utilization trends were robust during the second quarter, with hospital checks pointing to high single-digit volume growth - well above the historical average. Boston Scientific's main growth drivers, Farapulse and Watchman, which use short high-voltage pulses to treat certain abnormal heart rhythm conditions, saw strong demand during the quarter. Farapulse, approved in the U.S. to treat certain patients with intermittent atrial fibrillation, competes with Johnson & Johnson's Varipulse and Medtronic's PulseSelect in the market for pulsed field ablation (PFA) systems. "Cardiovascular end-markets remain robust," Truist analyst Richard Newitter said ahead of the earnings, adding that Boston, followed by Medtronic, are in the best position at the moment to benefit from the growing and accelerating PFA market. Rival Johnson & Johnson last week posted strong medtech sales, aided by its heart devices, Varipulse and Trupulse. Boston Scientific expects 2025 adjusted profit of $2.95 to $2.99 per share, up from the prior view of $2.87 to $2.94 earlier. It posted adjusted profit of 75 cents per share for the second quarter, topping analysts' average estimate of 72 cents, according to data compiled by LSEG. The company's cardiovascular unit reported quarterly sales of $3.34 billion, surpassing estimates of $3.20 billion. Revenue came in at $5.06 billion for the quarter, topping estimates of $4.9 billion.

One A Day® Launches First of its Kind Multivitamin Gummy with Iron to Help Fill Nutrient Gaps in Kids
One A Day® Launches First of its Kind Multivitamin Gummy with Iron to Help Fill Nutrient Gaps in Kids

Yahoo

time24 minutes ago

  • Yahoo

One A Day® Launches First of its Kind Multivitamin Gummy with Iron to Help Fill Nutrient Gaps in Kids

One A Day® Kids Multi with Iron provides 2/3 of the recommended daily value of Iron and is one of three offerings in the new Kids' line WHIPPANY, N.J., July 23, 2025--(BUSINESS WIRE)--One A Day®, the multivitamin and supplement brand rooted in 80+ years of nutritional science, announced the launch of One A Day® Kids Multi with Iron, a gummy multivitamin with 12mg of iron per serving1—no kids multivitamin gummy among leading brands has more iron—to help fill nutrient gaps kids may have. Iron is an essential mineral for healthy growth and development. As picky eating behavior is common according to a new survey sponsored by One A Day®, children may be falling short of important nutrients like iron. The survey sponsored by One A Day® reveals that mealtime can often feel like a standoff for parents and kids, with approximately two-thirds (66%) sharing that their child refuses meals at least once a week and more than half (54%) say their child mostly eats snacks, while refusing full meals. This can make it challenging to help kids get enough of the key nutrients they may need for healthy development and highlights the need for nutritional support during this picky phase. The survey also found that over half (51%) of parents worry their child's eating habits will affect growth and development, with 46% saying that managing their child's eating habits is a top parenting concern – even ahead of screentime. To shed light on the ways that parents can help kids get enough daily nutrients, One A Day® Kids is partnering with Dr. Jessica Andrade, board certified pediatrician. "Through my experience working with children and their families, I know how important good, balanced nutrition is for supporting kids' healthy development," shares Dr. Andrade. "Iron is one of the most common nutritional deficiencies in children, and it is crucial to their development. Adding these vitamin gummies to children's daily routines is a simple and tasty way to help meet daily iron needs, especially when they may lack iron in their diets." One A Day® Kids Multi with Iron is one of three offerings in the new One A Day Kids' line. These easy-to-chew gummy multivitamins are specially formulated with key nutrients for kids to support overall healthy growth and development as well as eye, brain, and immune health. One A Day® Kids Multi with Iron Gummies provides key nutrients and an excellent source of iron with 12mg of iron in two gummies a day – providing ⅔ of the recommended Daily Value for this key nutrient. One A Day® Kids Multi With Probiotic Gummies contains essential nutrients, and a probiotic clinically tested in kids. It includes 1 billion CFUs of Bacillus Subtilis DE111® probiotic per serving (2 gummies) to support gut health. One A Day® Kids Multi Gummies is formulated with 9 key vitamins and minerals, offering nutritional support in delicious natural fruit flavors orange, raspberry, and cherry2. "As a brand dedicated to providing consumers with nutritional support at important life stages, we know how important it is for parents to have a trusted multivitamin that kids actually want to take because they like the taste and texture. That's why we are excited to introduce the new One A Day® Kids line including the first of its kind gummy multivitamin with iron for kids," says Lisa Perez, mom of three and General Manager Nutritionals at Bayer, the maker of One A Day®. One A Day® Kids Gummies are formulated with good stuff parents want, without stuff they don't: free of artificial sweeteners, high fructose corn syrup and egg, fish/crustacean shellfish, and dairy (milk) – making them a great option for helping little ones thrive. With this launch, One A Day® reaffirms its commitment to providing consumers with high-quality multivitamins specially designed for different life stages, genders, ages, or health goals. For more information on One A Day® Kids, visit Benefit claims for One A Day(R) Kids Multi Gummies have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. DE111(R) is a trademark of Deerland Probiotics & Enzymes, Inc. 1 One serving = two gummies 2 Natural orange, raspberry and cherry flavors with other natural flavors Research MethodologyBayer sponsored an online survey for One A Day® Vitamins from 3/19/2025 to 3/23/2025 to explore how pickiness manifests in children and understand the real-life impact it has on parents. The survey included 1,000 U.S. adults with children ages 4-10 years old, balanced by gender and region to reflect U.S. census demographics. About One A Day®One A Day is a multivitamin and supplement brand offering specially formulated products for many members of the family. From prenatal to 65+, One A Day offers products for different ages, genders and health goals. The portfolio includes tablet, softgel, capsule, and gummy products. One A Day products are available at most major drug stores and retailers nationwide. About BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, "Health for all, Hunger for none," the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. View source version on Contacts Jan SchlegelmilchDirector, Integrated Communications, U.S. Consumer Bryan GibbsVice President, Media, twelvenote agencybgibbs@ Sign in to access your portfolio

High Quality, Increased Member Satisfaction, Better Access to Care and Improved Outcomes Highlight Alignment Healthcare's Impact in 2024
High Quality, Increased Member Satisfaction, Better Access to Care and Improved Outcomes Highlight Alignment Healthcare's Impact in 2024

Yahoo

time24 minutes ago

  • Yahoo

High Quality, Increased Member Satisfaction, Better Access to Care and Improved Outcomes Highlight Alignment Healthcare's Impact in 2024

New report outlines impact of company's commitment to always putting seniors first ORANGE, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC) today released its 2024 Impact Report outlining how it continued to deliver high-quality, personalized care to seniors while creating a positive impact on its members, providers, employees and the communities it serves. "As America's senior population rapidly grows, Alignment Healthcare is redefining what's possible in health care by combining compassion, innovation and accountability," said John Kao, founder and CEO, Alignment Healthcare. "Our Impact Report reflects our commitment to putting seniors first, empowering providers, leveraging data-driven care, and leading with a serving heart to create a better way to age in America." Noteworthy Highlights from the 2024 Impact Report include:Better Access to Care Served 11,500 members through the company's signature Care Anywhere program in 2024, a 35% increase from 8,500 members in 2023. The program helped remove barriers to access for high-risk members by offering in-home and virtual care, supported by a 24/7 virtual care center. Drove a 95% year-over-year increase in ACCESS On-Demand Concierge Card transactions to 3.1 million in 2024, almost double the use of eligible grocery purchases and over-the-counter items. Usage of the debit card grew from 97,000 members in 2023 to 151,000 in 2024. Expanded caregiver benefit access by almost 86%, with eligible members rising from 63,000 in 2023 to 117,000 in 2024. Launched in 2023, Alignment's benefit recognizes and supports those caring for the aging population. Improved Health Outcomes Achieved the company's lowest hospitalization rate to date: 149 hospitalizations per 1,000 members in 2024 – down nearly 4.5% from 156 hospitalizations per 1,000 members in 2023. This reflects impact of Alignment's proactive, preventive care approach. Reported 47% fewer skilled nursing facility admissions compared to the 2019 Medicare fee-for-service (FFS) benchmark, up from a 45% reduction in 2023. Delivery of Innovative, Data-Driven Care Enhanced care delivery through the integration of new capabilities in AVA®, Alignment's proprietary technology platform, including streamlined health risk assessments and condition tracking; simplified mental health benefit navigation and in-network appointment scheduling; and virtual care coordination enhancements such as integrated on-demand visit scheduling and appointment booking tools. Reduced 45 minutes of administrative wait time per member by leveraging AVA's provider integration. Increased Quality and Member Satisfaction Increased percentage of members enrolled in 4-star or higher-rated plans from 90% in 2023 to 100% of members in 2024. Achieved an overall Net Promoter Score (NPS) of 61, significantly higher than the industry average of 40, with the Care Anywhere program earning an NPS of 78. Maintained an average 4.9-out-of-5 Google review rating across more than 10,000 reviews. Commitment to Employees and Serving Responsibly Prioritized employee well-being and experience while offering comprehensive benefits, resulting in an 89% participation rate in the annual employee engagement survey and a 77% engagement index. Reduced greenhouse gas emissions by 36% compared to 2023, which is roughly equivalent to the annual energy use of 43.5 average U.S. homes or charging 26 million smartphones.1 The 2024 Impact Report reinforces Alignment's mission to provide compassionate, personalized care that addresses the holistic needs of America's growing senior population. To learn more, visit About Alignment HealthAlignment Health is championing a new path in senior care that empowers members to age well and live their most vibrant lives. A consumer brand name of Alignment Healthcare (NASDAQ: ALHC), Alignment Health's mission-focused team makes high-quality, low-cost care a reality for its Medicare Advantage members every day. Based in California, the company partners with nationally recognized and trusted local providers to deliver coordinated care, powered by its customized care model, 24/7 concierge care team and purpose-built technology, AVA®. As it expands its offerings and grows its national footprint, Alignment upholds its core values of leading with a serving heart and putting the senior first. For more information, visit Media ContactPriya ShahmPR, Inc. for Alignment Healthalignment@ 1 US EPA. (2025, February 24). Greenhouse Gas Equivalencies Calculator. US EPA. in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store